JP Morgan Upgrades AnaptysBio to Overweight, Raises Price Target to $69
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama has upgraded AnaptysBio (NASDAQ:ANAB) from Neutral to Overweight and raised the price target from $29 to $69.
July 19, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan analyst Anupam Rama has upgraded AnaptysBio from Neutral to Overweight and significantly raised the price target from $29 to $69. This indicates a strong positive outlook for the stock.
The upgrade from Neutral to Overweight by a major financial institution like JP Morgan, along with a substantial increase in the price target, suggests a strong positive sentiment towards AnaptysBio. This is likely to attract investor interest and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100